Bi-Annual Hypertension Injections Could Revolutionize Care While Sparking Warnings Against Physician and Patient Moral Hazard

New siRNA therapies like zilebesiran offer 6-month blood pressure control, but doctors warn of a "moral hazard" where patients might skip healthy lifestyle habits.

By: AXL Media

Published: Apr 28, 2026, 5:58 AM EDT

Source: Information for this report was sourced from Journal of Human Hypertension

The Paradox of Daily Behavioral Achievement

Hypertension remains a global medical paradox, staying a leading cause of disability despite the existence of numerous effective pharmacological treatments. Current care models rely on "behavioral achievement," requiring asymptomatic patients to remember daily pill regimens without immediate physiological feedback. According to the Journal of Human Hypertension perspective, this system essentially acts as a social filter that tracks life stability rather than clinical need, resulting in fewer than 25% of hypertensive individuals achieving controlled blood pressure levels globally.

Pharmacological Shift From Patient to System

The emergence of small-interfering RNA (siRNA) therapies, specifically zilebesiran, marks a fundamental shift in how responsibility for cardiovascular protection is distributed. By targeting hepatic angiotensinogen (AGT) to suppress the renin-angiotensin-aldosterone system, a single subcutaneous injection can maintain lowered blood pressure for up to six months. This transition moves the burden of care from the patient's daily memory to the healthcare system's administrative reliability, effectively treating hypertension with a cadence similar to a semi-annual vaccine.

Clinical Evidence From the KARDIA Trial Program

Recent clinical data from the Phase 2 KARDIA-1 study demonstrated that quarterly or bi-annual doses of zilebesiran achieved sustained reductions in 24-hour mean systolic blood pressure, with some doses showing placebo-adjusted drops of up to 15 mmHg at three months. However, the KARDIA-3 trial, which focused on higher-risk patients already on multiple medications, missed its primary endpoint after multiplicity adjustments. Despite this, the scientific community remains optimistic, as the totality of the Phase 2 data has informed the design of the upcoming ZENITH trial, a massive 11,000-patient investigation into major cardiovascular outcomes.